<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00343083</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00042712</org_study_id>
    <secondary_id>CA225092</secondary_id>
    <nct_id>NCT00343083</nct_id>
  </id_info>
  <brief_title>Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel &amp; Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)</brief_title>
  <official_title>A Phase II Study of Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel &amp; Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Department of Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the response of the tumor to the treatment regimen
      that will be used in this study. This study will also test the safety of cetuximab (C225),
      given with chemotherapy and radiation therapy. We also want to see what effects (good and
      bad) cetuximab, chemotherapy, and radiation therapy have head &amp; neck cancer.

      C225 has been designed to stop the growth of the tumor by blocking certain chemical pathways
      that lead to tumor cell growth. In prior studies with head &amp; neck cancer patients, C225 has
      delayed tumor growth and provided relief of symptoms in some patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective- To evaluate whether the addition of Cetuximab (C225) in combination with
      chemotherapy and radiation can cause an enhanced anti-tumor effect resulting in improving
      local regional control of patients with locally advanced, unresectable squamous cell
      carcinoma of head and neck. (SCCHN).

      OVERVIEW OF STUDY DESIGN Open label, non-randomized, single arm trial.

      P = Paclitaxel will be administered on a weekly schedule at a dose of 40mg/m2 IV by 1-hour
      infusion prior to cetuximab dose. This will be administered for a total of 8 weeks (from
      weeks 2-9)

      C225 = Cetuximab: 400 mg/m2 IV will be given as the initial OR loading dose in week 1 and
      then 250 mg/m2 IV weekly will be given for 8 weeks (weeks 2-9).

      C = Carboplatin will be given at a dose of AUC=2/week - will be administered as a 30 minute
      infusion after cetuximab infusion (weeks 2-9)

      RT = Radiation therapy will be delivered at 1.8 Gy fraction/day, 5 days a week for a total of
      70.2 Gy. RT will be given from weeks 2-9.

      Note: Sequence of administration will be paclitaxel followed by cetuximab followed by
      carboplatin followed by XRT.

      Approximately 60 patients from MSGCC/BVAMC will participate in this study. Prior to entering
      the study the doctor will examine the patient and order blood tests ( which will be done by
      blood draw, approximately 2 tablespoons) and tests to measure the patients disease (scans).
      The patient will also be evaluated by a dietician who will follow the patient throughout the
      course of the therapy to help the patient meet his/her nutritional needs
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Endpoint is the Local Regional Control Rate Assessed 3 Months Post Completion of Radiation Therapy.</measure>
    <time_frame>3 months</time_frame>
    <description>The local regional control rate was assessed 3 months post completion of radiation therapy based on either MRI or CT and clinical exam.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Regional Control at 2 Years</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival and Disease-free Survival</measure>
    <time_frame>3 years (overall) 2 years disease-free</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological Response to Cetuximab</measure>
    <time_frame>2 years</time_frame>
    <description>Adding CTX to weekly PC and daily RT. CBC and Chemistry panel blood testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Grade 3 Toxicities of Cetuximab</measure>
    <time_frame>9 weeks</time_frame>
    <description>One of the more serious side effects of cetuximab therapy is the incidence of acne-like rash. This rash rarely leads to dose reductions or termination of therapy. It is generally reversible.
Further severe infusion reactions include but are not limited to: fevers, chills, rigors, urticaria, pruritis, rash, hypotension, N/V, HA, bronchospasm, dyspnea, wheezing, angioedema, dizziness, anaphylaxis, and cardiac arrest. Therefore, pretreatment with diphenhydramine 30-60 min. before administration is standard of care. Other common side effects include photosensitivity, hypomagnesemia due to magnesium wasting, and less commonly pulmonary and cardiac toxicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Complete Response Rate of This Regimen in the Population</measure>
    <time_frame>3 months</time_frame>
    <description>What is the the complete response (CR) rate at the completion of therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Cancer of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Cetuximab comparison for Head and Neck Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To report the mature data of a prospective Phase II trial designed to evaluate the efficacy of an epidermal growth factor receptor inhibitor cetuximab (CTX) added to the concurrent therapy of weekly paclitaxel/carboplatin (PC) and daily radiation therapy (RT).
Both chemotherapy and radiation will be given on a weekly basis (see interventions for details).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erbitux, Paclitaxel &amp; Carboplatin</intervention_name>
    <description>Paclitaxel, 40 mg/m2/week,
1-hour infusion (weeks 2-9.Paclitaxel will be administered on a weekly schedule at a dose of 40mg/m2 IV by 1-hour infusion prior to cetuximab dose.
Cetuximab: 400 mg/m2 IV (initial dose) week 1 then 250 mg/m2 IV weekly for 8 weeks weeks 2-9). Cetuximab will be administered 400mg/m2 IV on Day 1, then the first 250 mg/m2 IV dose will be given on day 8 (week 2) prior to carboplatin dose.
Carboplatin, AUC=2/week as a 30 minute infusion after cetuximab infusion (weeks 2-9)Carboplatin will be administered at a dose of AUC = 2/week IV bolus each week and will be administered prior to head and neck irradiation dose. (Carboplatin: AUC=2/week x 8 weeks (weeks 2-9)</description>
    <arm_group_label>Cetuximab comparison for Head and Neck Cancer</arm_group_label>
    <other_name>Taxol, Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>XRT=Radiotherapy 1.8 Gy radiation/day, 5 days a week for a total of 70.2 Gy.(weeks 2-9) - IMRT is allowed</description>
    <arm_group_label>Cetuximab comparison for Head and Neck Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proved locally advanced squamous cell carcinoma of the head and neck of
             all primary sites. The following TNM stages by sites will be eligible.Oral cavity,
             Pharynx, Larynx, Nasopharynx, paranasal sinuses, Oral cavity, Pharynx, Larynx,
             Nasopharynx, paranasal sinuses- T4 N0 N1 N2-A,B,C N3, T3 N0 N1 N2-A,B,C N3 Any T
             N2-A,B,C N3 Unknown primary Tx N2-A,B,C N3 Note: Only clearly unresectable T4 N0
             lesions are eligible for study provided the reasons for unresectability are due to
             extensive anatomic involvement and are outlined by the surgeon

          2. Patients must have signed an approved informed consent.

          3. Patients with Performance Status 0-2.

          4. No evidence of distant metastatic disease.

          5. No previous radiation therapy.

          6. No previous chemotherapy.

          7. Patients must be greater than 18 years of age.

          8. Women of child bearing potential (WOCBP) must have a negative pregnancy test within 7
             days of treatment. Patients are considered not of child bearing potential if they are
             surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or
             bilateral oophorectomy) or they are postmenopausal.

          9. Pretreatment evaluations include:

             History and physical examination within four weeks prior to study entry Dental
             evaluation Medical oncology examination to evaluate medical contraindications prior to
             start of chemotherapy

         10. Adequate renal &amp; bone marrow function determined by the following laboratory
             parameters:

             ANC greater than or equal to 1500/mm3; platelets greater than or equal to 100,000/mm3;
             hemoglobin greater than or equal to 8.0 g/dl; Serum Creatinine less than or equal to
             2.0 mg/dl, Total bilirubin less than 1.5 X the ULIN; AST/ALT less than 3 times the
             ULN, Creatinine Clearance greater than or equal to 50 cc/min

         11. Evidence of measurable disease.

         12. No evidence of concomitant malignancy except for non-melanomatous skin cancer
             (controlled or controllable) or carcinoma in situ of the cervix.

        Exclusion Criteria:

        Any of the following criteria will make the patient ineligible to participate in this
        study:

          1. Acute hepatitis or known HIV.

          2. Active or uncontrolled infection.

          3. Significant history of concomitant life threatening / uncontrolled cardiac disease;
             i.e., uncontrolled hypertension, unstable angina, recent myocardial infarction (within
             prior 6 months), uncontrolled congestive heart failure, and known cardiomyopathy with
             decreased ejection fraction, cardiac arrhythmia

          4. Prior therapy which specifically and directly targets the EGFR pathway.

          5. Prior severe infusion reaction to a monoclonal antibody.

          6. Any concurrent chemotherapy not indicated in the study protocol or any other
             investigational agent(s).

          7. Women of childbearing potential (WOCBP) and male participants who are unwilling or
             unable to use an effective method to avoid pregnancy for the entire study period

          8. Preexisting clinically significant neuropathy.

          9. Patients with loco-regional recurrences from any site with no prior radiation therapy
             and not amenable for salvage surgery are not eligible for study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohan Suntharalingam, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland &amp; Baltimore VA medical centre</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2006</study_first_submitted>
  <study_first_submitted_qc>June 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2006</study_first_posted>
  <results_first_submitted>April 12, 2013</results_first_submitted>
  <results_first_submitted_qc>April 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2014</results_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Department of Radiation Oncology</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Head and Neck Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cetuximab (ERBITUX) and Concurrent Carboplatin</title>
          <description>. Radiation will be given at a dose of 1.8 Gy. for a total of 70.2 Gy. Chemotherapy will be given every week for a total of 8 weeks. Paclitaxel will be given at a dose of 40 mg/m2 as a 1 hour infusion dose followed by cetuximab and then carboplatin AUC = 2/week.
The initial dose of cetuximab is 400 mg/m2 IV on day 1, followed by weekly infusions at 250 mg/m2 IV.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cetuximab (ERBITUX) and Concurrent Carboplatin</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint is the Local Regional Control Rate Assessed 3 Months Post Completion of Radiation Therapy.</title>
        <description>The local regional control rate was assessed 3 months post completion of radiation therapy based on either MRI or CT and clinical exam.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Concurrent Chemo Raditaion Wtih Cetuximab</title>
            <description>The addition of CTX to weekly PC and daily RT.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint is the Local Regional Control Rate Assessed 3 Months Post Completion of Radiation Therapy.</title>
          <description>The local regional control rate was assessed 3 months post completion of radiation therapy based on either MRI or CT and clinical exam.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Regional Control at 2 Years</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Concurrent Chemo Raditaion Wtih Cetuximab</title>
            <description>The addition of CTX to weekly PC and daily RT.</description>
          </group>
        </group_list>
        <measure>
          <title>Local Regional Control at 2 Years</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival and Disease-free Survival</title>
        <time_frame>3 years (overall) 2 years disease-free</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Concurrent Chemo Raditaion Wtih Cetuximab</title>
            <description>The addition of CTX to weekly PC and daily RT.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival and Disease-free Survival</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>overall survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>disease-free survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathological Response to Cetuximab</title>
        <description>Adding CTX to weekly PC and daily RT. CBC and Chemistry panel blood testing</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Concurrent Chemo Raditaion Wtih Cetuximab</title>
            <description>The addition of CTX to weekly PC and daily RT</description>
          </group>
        </group_list>
        <measure>
          <title>Pathological Response to Cetuximab</title>
          <description>Adding CTX to weekly PC and daily RT. CBC and Chemistry panel blood testing</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Grade 3 Toxicities of Cetuximab</title>
        <description>One of the more serious side effects of cetuximab therapy is the incidence of acne-like rash. This rash rarely leads to dose reductions or termination of therapy. It is generally reversible.
Further severe infusion reactions include but are not limited to: fevers, chills, rigors, urticaria, pruritis, rash, hypotension, N/V, HA, bronchospasm, dyspnea, wheezing, angioedema, dizziness, anaphylaxis, and cardiac arrest. Therefore, pretreatment with diphenhydramine 30-60 min. before administration is standard of care. Other common side effects include photosensitivity, hypomagnesemia due to magnesium wasting, and less commonly pulmonary and cardiac toxicity.</description>
        <time_frame>9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Concurrent Chemo Raditaion Wtih Cetuximab</title>
            <description>The addition of CTX to weekly PC and daily RT</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Grade 3 Toxicities of Cetuximab</title>
          <description>One of the more serious side effects of cetuximab therapy is the incidence of acne-like rash. This rash rarely leads to dose reductions or termination of therapy. It is generally reversible.
Further severe infusion reactions include but are not limited to: fevers, chills, rigors, urticaria, pruritis, rash, hypotension, N/V, HA, bronchospasm, dyspnea, wheezing, angioedema, dizziness, anaphylaxis, and cardiac arrest. Therefore, pretreatment with diphenhydramine 30-60 min. before administration is standard of care. Other common side effects include photosensitivity, hypomagnesemia due to magnesium wasting, and less commonly pulmonary and cardiac toxicity.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>leukopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RT dermatisis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Complete Response Rate of This Regimen in the Population</title>
        <description>What is the the complete response (CR) rate at the completion of therapy.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Concurrent Chemo Raditaion Wtih Cetuximab</title>
            <description>The addition of CTX to weekly PC and daily RT</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Complete Response Rate of This Regimen in the Population</title>
          <description>What is the the complete response (CR) rate at the completion of therapy.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cetuximab (ERBITUX) and Concurrent Carboplatin</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <description>3 patients developed a Grade IV anaphylactic reaction to the loading dose of Erbitux (week 1) and were taken off protocol hence withdrawn due to toxicity.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ritesh Kataria</name_or_title>
      <organization>University of Maryland Baltimore</organization>
      <phone>410-328-8018</phone>
      <email>rkataria@umm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

